IP Library Granted Patent US 8,455,436
Granted Patent B2
US 8,455,436 · App. 12/979,990 · Granted Jun 4, 2013

Compositions and methods for treating joints

Inventors: Ben Byers (North Easton, MA); Dongling Su (Franklin, MA); Julia Hwang (Wayland, MA)
Assignee: DePuy Mitek, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,455,436
App. No.
12/979,990
Granted
Jun 4, 2013
Kind
B2
Abstract

Methods and compositions are disclosed for an intra-articular injection for the treatment of osteoarthritis. The methods and compositions comprising combinations of hyaluronic acid and a bone morphogenetic protein, like rhGDF-5, can be useful for any synovial joint, including the knee, shoulder, hip, ankle, hands, spinal facet, or temporomandibular joint, both for the relief of pain and for slowing disease progression.

Claims (9)

1. A method for treating a joint condition, comprising:

combining a solution of hyaluronic acid (HA) with a bone morphogenetic protein (BMP) to form a mixture in which the BMP is precipitated and dispersed at a concentration in the range of about 5 μg/ml to 90 μg/ml in the solution of HA, the mixture having a pH in the range of about 3 to 8; and

injecting the mixture into a subject to treat the joint condition, the BMP being capable of becoming solubilized and biologically active within the subject after injection.

2. The method of claim 1 , wherein the BMP is a growth and differentiation (GDF) protein.

3. The method of claim 1 , wherein the BMP is in a liquid state prior to combining with the solution of HA.

4. The method of claim 1 , wherein the BMP is in a lyophilized state prior to combining with the solution of HA.

5. The method of claim 1 , wherein the mixture has a pH in the range of about 4 to 7.5.

6. The method of claim 1 , wherein the HA has a molecular weight of at least about 500 kDa.

7. The method of claim 1 , wherein the HA is at a concentration in the range of About 5 mg/ml to 60 mg/ml.

Assignments (9)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2019
From: SYNTHES USA, LLC
To: DEPUY SPINE, LLC
Reel/Frame 048829/0673 →
CHANGE OF NAME Recorded Jan 31, 2019
From: DEPUY SYNTHES PRODUCTS, LLC
To: DEPUY SYNTHES PRODUCTS, INC
Reel/Frame 048198/0563 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2019
From: DEPUY MITEK HOLDING CORPORATION
To: SYNTHES USA, LLC
Reel/Frame 048198/0860 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2019
From: DEPUY MITEK, LLC
To: DEPUY SYNTHES SALES, INC.
Reel/Frame 048197/0069 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2019
From: DEPUY SYNTHES SALES INC.
To: DEPUY SYNTHES PRODUCTS, INC.
Reel/Frame 048197/0142 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2019
From: DEPUY MITEK, LLC
To: DEPUY MITEK HOLDING CORPORATION
Reel/Frame 048197/0861 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2019
From: DEPUY SPINE, LLC
To: DEPUY SYNTHES PRODUCTS, LLC
Reel/Frame 048198/0497 →
CHANGE OF NAME Recorded Apr 18, 2013
From: DEPUY MITEK, INC.
To: DEPUY MITEK, LLC
Reel/Frame 030240/0705 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2011
From: BYERS, BEN; SU, DONGLING; HWANG, JULIA
To: DEPUY MITEK, INC.
Reel/Frame 025787/0129 →
Continuity (1)
Related Publication 20120165257A1 · Jun 28, 2012